Exciting News: SELARSDI™ Receives FDA Approval
Teva Pharmaceuticals, in collaboration with Alvotech, has made significant strides in the field of biosimilars. Recently, the U.S. Food and Drug Administration (FDA) granted approval for SELARSDI™ (ustekinumab-aekn), marking it as interchangeable with the established biologic, Stelara® (ustekinumab). This interchangeability is expected to go into effect on April 30, 2025, which is a notable advancement for patients in the U.S., providing them access to effective treatment options.
Understanding SELARSDI’s Indications
Who Can Benefit from SELARSDI?
The FDA approval encompasses all indications that match the original product. SELARSDI is designed for treating moderate to severe plaque psoriasis and active psoriatic arthritis in both adults and pediatric patients aged six and older. Additionally, it addresses the needs of adult patients suffering from moderately to severely active Crohn’s disease and ulcerative colitis. With this approval, the landscape of treatment options has broadened considerably, aiding both patients and healthcare providers in managing these chronic conditions.
Remarks from Top Officials
Teva’s Perspective on the Approval
Thomas Rainey, Senior Vice President of U.S. Biosimilars at Teva, commented on the significance of this development for the healthcare community. He stated, "The FDA’s confirmation of full interchangeability for SELARSDI is an important development for patients and providers seeking to expand access to this important treatment." This sentiment underscores the commitment of Teva towards enhancing healthcare access through biosimilars. The launch of SELARSDI, along with other products in their pipeline, positions Teva favorably in the competitive biosimilar market.
Alvotech’s Commitment to Affordable Treatments
Enhancing Healthcare Affordability
In a parallel statement, Anil Okay, Chief Commercial Officer for Alvotech, expressed optimism about the approval. He stated, "Interchangeability of SELARSDI with Stelara will further enable increased access for U.S. patients to more affordable treatment options..." Alvotech’s proactive development strategy aims at lowering healthcare costs and facilitating broader access to high-quality biologics. The company is committed to a comprehensive approach in bringing affordable medicines to the market, which aligns with their mission of serving patients globally.
Details on SELARSDI Presentations
The approved presentations of SELARSDI include several forms for different administration routes, such as 45 mg/0.5 mL and 90 mg/mL in a prefilled syringe for subcutaneous injections, and 130 mg/26 mL in a single-dose vial for those requiring intravenous infusion. This variety allows healthcare providers to choose the most suitable administration method based on patient needs.
Biological Mechanism of SELARSDI
SELARSDI operates as a human monoclonal antibody that specifically targets the p40 protein, which is common to interleukin-12 and interleukin-23 cytokines. These cytokines are crucial in managing immune-mediated conditions like psoriasis and psoriatic arthritis, as well as inflammatory diseases such as Crohn’s disease and ulcerative colitis. Alvotech employs a sophisticated development process for SELARSDI that mirrors the techniques used in producing Stelara, ensuring a comparable quality and efficacy.
Collaboration Between Teva and Alvotech
Teva and Alvotech have entered into a strategic partnership aimed at commercializing several biosimilar product candidates. Their collaboration was initially established in 2020, focusing on the exclusive commercialization of five Alvotech biosimilars, which has since expanded to include additional products. This partnership reflects their shared ambition to enhance the availability of biosimilars in the market, benefiting healthcare systems and patients alike.
Future Aspirations in the Biologics Space
As they look forward, both companies are committed to shaping the future of biosimilars. Alvotech currently has additional biosimilar candidates under review with the FDA, including those targeting existing biologics such as Simponi® (golimumab) and Eylea® (aflibercept). With multiple submissions in progress, Alvotech and Teva are poised to increase their impact in the biosimilars market significantly.
Frequently Asked Questions
What is SELARSDI™?
SELARSDI™ is a biosimilar approved by the FDA, interchangeable with Stelara® for treating several immune-mediated diseases.
Who developed SELARSDI™?
SELARSDI is developed and manufactured by Alvotech, in partnership with Teva Pharmaceuticals for commercialization.
What conditions does SELARSDI™ treat?
SELARSDI™ is indicated for moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn's disease, and ulcerative colitis.
When will SELARSDI™ be available?
SELARSDI™ is expected to be available as of April 30, 2025.
How does SELARSDI™ work?
SELARSDI™ is a monoclonal antibody that targets specific proteins in the immune system, playing a vital role in the treatment of inflammatory diseases.
